


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

ANNOUNCEMENT OF 2010 ESTIMATED INTERIM RESULTS

This announcement is made pursuant to Rule 13.09 of the Listing Rules.

Based on the preliminary management accounts prepared by the Group in accordance with HKFRSs, the net profit of the Group for the six months ended 30 June 2010 is expected to be at least 3.5 times of that for the six months ended 30 June 2009.

The financial information of the Group for the six months ended 30 June 2010 referred to in this announcement is preliminary, unaudited, and may be different from the interim financial information to be published. The Board confirmed that the disclosure of the financial information of the Group for the six months ended 30 June 2010 referred to in this announcement is made after due and careful enquiry.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the "Listing Rules") on The Stock Exchange of Hong Kong Limited.

The board of the directors (the "Board") of The United Laboratories International Holdings Limited (the "Company") announces the estimated interim results of the Company and its subsidiaries (the "Group") for the six months ended 30 June 2010 as follows:

(1) Estimated results for the six months ended 30 June 2010

Based on the preliminary management accounts prepared by the Group for the six months ended 30 June 2010 in accordance with Hong Kong Financial Reporting Standards (“HKFRSs”), the estimated net profit of the Group for the six months ended 30 June 2010 is expected to be at least 3.5 times of that for the six months ended 30 June 2009. Detailed financial information will be published in the forthcoming 2010 interim report of the Company.

The financial information of the Group for the six months ended 30 June 2010 referred to in this announcement is preliminary, unaudited, and may be different from the interim financial information to be published. The Board confirmed that the disclosure of the financial information of the Group for the six months ended 30 June 2010 referred to in this announcement is made after due and careful enquiry.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

(2) Results of the corresponding period in 2009

The net profit attributable to the shareholders of the Company for the six months ended 30 June 2009 was HK\$134,445,000.

The earnings per share of the Company for the six months ended 30 June 2009 was HK\$0.112.

The above financial figures were prepared in accordance with HKFRSs.

(3) Reason for increase in results

The increase in net profit for the six months ended 30 June 2010 was mainly attributable to the satisfactory increase in sales of intermediate products, bulk medicine products and finished products of the Group.

By Order of the Board
**The United Laboratories
International Holdings Limited**
Choy Kam Lok
Chairman

Hong Kong, 26 July 2010

As at the date of this announcement, the Board comprises Mr. Choy Kam Lok, Ms. Peng Wei, Mr. Leung Wing Hon and Mr. Tsoi Hoi Shan as executive directors; Ms. Choy Siu Chit as non-executive director; and Mr. Chong Peng Oon, Mr. Huang Bao Guang and Mr. Song Ming as independent non-executive directors.